Global Presbyopia Correction Device Market Size By Type (Corneal Inlays, Scleral Implants), By Application (Age 40-50, Age 50-65), By Region, And Segment Forecasts, 2023 to 2032

The Global Presbyopia Correction Device Market was valued at USD 4.7 billion in 2023 and is projected to reach USD 8.1 billion by 2031, expanding at a CAGR of 6.9% during the forecast period of 2023–2031. The market is witnessing steady growth driven by the rising prevalence of presbyopia among the aging global population, advancements in vision correction technologies, and increasing demand for minimally invasive and device-based treatment options over traditional corrective methods such as eyeglasses or contact lenses.

Presbyopia, an age-related condition leading to the gradual loss of near vision, affects over 1.8 billion people globally. Correction devices, including corneal inlays, scleral implants, intraocular lenses, and laser-based devices, are increasingly being adopted to improve patients’ quality of life with long-term solutions.

Drivers:

1. Rising Aging Population:

The growing elderly demographic worldwide, particularly those aged 40 and above, is significantly contributing to the demand for presbyopia correction devices.

2. Technological Advancements in Vision Correction:

Continuous innovation in ophthalmic technologies, such as laser vision correction systems and advanced intraocular lenses (IOLs), has made surgical and device-based solutions more effective, safer, and widely accessible.

3. Shift Toward Minimally Invasive Procedures:

Consumer preference is shifting towards non-invasive or minimally invasive corrective solutions that offer faster recovery and lasting results, fostering adoption of presbyopia correction devices.

Restraints:

1. High Procedure and Device Cost:

The cost associated with advanced surgical correction devices remains high, limiting accessibility in low- and middle-income regions.

2. Regulatory Challenges:

Presbyopia correction devices often require stringent regulatory approval, which can delay market entry and affect the pace of innovation.

Opportunity:

1. Emerging Markets Expansion:

Countries in Asia-Pacific and Latin America present untapped growth potential due to rising healthcare awareness, expanding medical infrastructure, and increasing disposable income.

2. Integration of AI and Smart Diagnostics:

The incorporation of artificial intelligence in diagnostic and surgical planning for presbyopia correction opens up avenues for personalized treatment and improved patient outcomes.

Market by System Type Insights:

By system type, Intraocular Lenses (IOLs) dominated the market in 2023, capturing the largest revenue share. IOLs are preferred for their long-term correction capability and dual benefits in treating both cataracts and presbyopia. The Corneal Inlays segment is anticipated to exhibit the fastest growth due to their reversible nature and suitability for patients reluctant to undergo lens replacement surgery.

Market by End-Use Insights:

Based on end-use, Ophthalmology Clinics held the majority share in 2023, accounting for over 45% of the market, due to high procedure volumes and specialization. However, Ambulatory Surgical Centers (ASCs) are expected to witness robust growth owing to shorter recovery times, cost-efficiency, and growing adoption of outpatient eye care procedures.

Market by Regional Insights:

North America led the global market in 2023, supported by advanced healthcare infrastructure, high awareness levels, and strong presence of key players. Asia-Pacific is projected to experience the fastest CAGR during the forecast period, driven by an increasing presbyopic population, rising healthcare expenditure, and the expanding availability of ophthalmic devices.

Competitive Scenario:

Key players operating in the Global Presbyopia Correction Device Market include:

Johnson & Johnson Vision

Alcon Inc.

Carl Zeiss Meditec AG

Bausch + Lomb

RxSight, Inc.

Presbia PLC

Ziemer Ophthalmic Systems AG

SCHWIND eye-tech-solutions GmbH

AcuFocus, Inc.

LensGen, Inc.

These companies focus on R&D, FDA approvals, and strategic collaborations to broaden their portfolios. Notable developments include:

2023: Johnson & Johnson Vision launched a next-generation multifocal IOL with enhanced contrast sensitivity.

2024: RxSight received expanded FDA approval for its light-adjustable lens technology.

2025: Alcon announced a strategic partnership with a digital diagnostics startup to enhance AI integration in presbyopia correction planning.

Scope of Work – Global Presbyopia Correction Device Market

Report Metric Details

Market Size (2023) USD 4.7 billion

Projected Market Size (2031) USD 8.1 billion

CAGR (2023–2031) 6.9%

Key Segments System Type (IOLs, Corneal Inlays), End-use (Hospitals, Clinics, ASCs)

Growth Drivers Aging population, device innovation, preference for minimally invasive procedures

Opportunities Expansion in emerging markets, AI-driven diagnostics

Key Market Developments:

May 2023: Alcon introduced a new trifocal IOL for presbyopia with enhanced vision under varying light conditions.

February 2024: Presbia resumed commercialization of its microlens corneal inlay post regulatory re-clearance in Europe.

January 2025: LensGen completed Phase III trials of its accommodating IOL, demonstrating promising efficacy and safety.

FAQs:

What is the current market size of the Global Presbyopia Correction Device Market?

The market was valued at USD 4.7 billion in 2023.

What is the major growth driver of the Global Presbyopia Correction Device Market?

The key driver is the growing global aging population and advancements in vision correction technology.

Which is the largest region during the forecast period in the Global Presbyopia Correction Device Market?

North America held the largest market share in 2023.

Which segment accounted for the largest market share in the Global Presbyopia Correction Device Market?

Intraocular Lenses (IOLs) led the market by system type in 2023.

Who are the key market players in the Global Presbyopia Correction Device Market?

Major players include Johnson & Johnson Vision, Alcon Inc., Carl Zeiss Meditec AG, Bausch + Lomb, and RxSight, Inc.